WGSNasdaqServices-Health ServicesUS GAAP · USD

GeneDx Holdings Corp.

GeneDx Holdings Corp. is a U.S.-based genomics diagnostics and data company focused on exome and genome sequencing for rare disease, hereditary risk, and cancer. It combines clinical testing, interpretation software, and a proprietary dataset to help clinicians reach faster, more actionable genetic diagnoses, while also monetizing data, bio-pharma programs, and software subscriptions through Fabric Genomics.

Kysy yhtiöstä
Liikevaihto428milj. USD
+40,0 %v/v
Liikevoitto (EBIT)−13,1milj. USD
+43,7 %v/v
EBIT-marginaali−3,1%
+4,5 %-yks.v/v
Nettotulos−21,0milj. USD
+59,8 %v/v
Vapaa kassavirta14,3milj. USD
+142,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−750−500−2500250500milj. USD2020: 179 milj. USD2020: EBIT −242 milj. USD20202021: 212 milj. USD2021: EBIT −446 milj. USD20212022: 235 milj. USD2022: EBIT −668 milj. USD20222023: 203 milj. USD2023: EBIT −181 milj. USD20232024: 305 milj. USD2024: EBIT −23 milj. USD20242025: 428 milj. USD2025: EBIT −13 milj. USD2025428−13
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: GeneDx Holdings Corp.

Liiketoiminta

Osuus liikevaihdosta
Diagnostic test revenue92 %

Clinical exome and genome sequencing tests and related diagnostic reports sold to healthcare providers and payors.

Software and interpretation services3 %

Fabric Genomics software subscriptions plus interpretation and consulting services for genomic workflows.

Data and bio-pharma programs3 %

Data licensing, research collaborations, and bio-pharma programs built on the GeneDx dataset.

Other services and products2 %

Newborn screening products, information services, and other smaller revenue streams.

Tuotteet

Raportoitu · osuus liikevaihdosta
80,7%16,4%FY2025100 %
  • Diagnostic Test Third Party Insurance80,7 %
  • Diagnostic Test Institutional Customers16,4 %
  • Other2,5 %
  • Diagnostic Test Self Pay0,3 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

GeneDx sells primarily into the healthcare system, with payment coming from third-party payors, patients, and business-to-business partners. Its core buyers are clinicians and institutions that need genetic testing and interpretation for rare disease, hereditary risk, and cancer cases, while research and biopharma customers use the company’s dataset and software capabilities.

Third-party payors

Insurers and managed care organizations reimburse diagnostic test reports and strongly influence pricing and volume.

Clinicians and hospitals

Hospitals, genomic centers, and physicians order exome and genome tests to diagnose rare and complex conditions.

Clinical laboratories

Labs buy software subscriptions and interpretation tools to support genomic workflows and reporting.

Research institutions

Academic and research customers use data, analysis, and consulting services for discovery and studies.

Biopharma partners

Drug developers use the GeneDx dataset and collaboration programs to support target discovery and evidence generation.

Strategia

GeneDx is investing in platform innovation to expand beyond a pure diagnostic testing model into software, data, and interpretation services. The strategy centers on growing exome and genome volumes, improving reimbursement and test mix, and using acquisitions such as Fabric Genomics to deepen AI-enabled interpretation and broaden customer reach.

Scale exome and genome testingLyhyt aikaväli

These tests are the main revenue engine and benefit from higher reimbursement and better economics.

Expand software and interpretation offeringsKeskipitkä aikaväli

Recurring software and services can diversify revenue beyond diagnostic reports.

Build data and biopharma monetizationKeskipitkä aikaväli

The proprietary dataset can support research partnerships and higher-margin adjacent revenue.

Maantiede

GeneDx is overwhelmingly U.S.-centric, with substantially all revenue tied to domestic diagnostic testing and healthcare reimbursement. Management disclosed that about 1.5% of revenue currently comes from referral sources outside the United States, but it expects international revenue to grow over time as exome and genome sequencing adoption expands.

Riskit

GeneDx faces reimbursement, adoption, and competitive risks because most revenue depends on diagnostic testing and payor coverage. It also has integration and execution risk from acquisitions, plus exposure to regulatory, legal, and accounting judgments tied to complex contracts, contingent liabilities, and fair value estimates.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Reimbursement pressure1Competitive intensity2Acquisition integration risk3Revenue timing and contract variability4Legal and contingent liability exposure5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Reimbursement pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Diagnostic test revenue depends heavily on third-party payor coverage and pricing decisions.

    Kohdistuu: Exome and genome sequencing reimbursement

  2. Competitive intensityVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company competes with specialty labs, academic centers, and informatics providers.

    Kohdistuu: Clinical genetic testing and interpretation

  3. Acquisition integration riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Fabric Genomics and any future deals may be difficult to integrate and may not deliver expected benefits.

    KohdistuuTechnologySystemsOperating integration
  4. Revenue timing and contract variabilityVaikutus: KeskitasoTodennäköisyys: Matala

    Collaboration and service agreements can fluctuate with delivery patterns, milestones, and cost estimates.

    KohdistuuSoftwareDataPartner contracts
  5. Legal and contingent liability exposureVaikutus: KeskitasoTodennäköisyys: Matala

    The company has settlement obligations and fair value changes that can affect earnings and cash needs.

    Kohdistuu: Payor settlement and contingent liabilities

Kysy Clarifolta: GeneDx Holdings Corp.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for diagnostic and collaboration contracts

Different service lines may recognize revenue at different times, affecting quarterly comparability.

Vaikutus: Can shift reported revenue between periods

Fair value measurement of warrants and contingent liabilities

Changes in valuation assumptions can create large non-cash gains or losses.

Vaikutus: Impacts net income and non-operating results

Settlement and legal reserve accounting

The company has payor-related settlement obligations that require accrual and cash planning.

Vaikutus: Affects liabilities, cash flow, and earnings

Accounts receivable and reimbursement estimates

Growth in test volumes and reimbursement rates influences collectability and working capital.

Vaikutus: Affects operating cash flow and revenue realization

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Insight Molecular Diagnostics Inc.

IMDX · In Vitro & In Vivo Diagnostic Substances

10x Genomics, Inc.

TXG · Laboratory Analytical Instruments

Genprex, Inc.

GNPX · Pharmaceutical Preparations

Ginkgo Bioworks Holdings, Inc.

DNA · Biological Products, (No Diagnostic Substances)

Fulgent Genetics, Inc.

FLGT · Services-Medical Laboratories

Myriad Genetics, Inc

MYGN · In Vitro & In Vivo Diagnostic Substances

Päivitetty: 24.9.2026

GeneDx Holdings Corp. (WGS) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo